Dense-Dose Chemo of Little Benefit in Early Breast Cancer

Share this content:
Dense-Dose Chemo of Little Benefit in Early Breast Cancer
Dense-Dose Chemo of Little Benefit in Early Breast Cancer

WEDNESDAY, Nov. 9, 2016 (HealthDay News) -- Tailored dose-dense chemotherapy offers little benefit over standard chemotherapy for women with high-risk early breast cancer, according to research published in the Nov. 8 issue of the Journal of the American Medical Association.

Researchers from The Swedish Breast Cancer Group, led by Jonas Bergh, M.D., of the Karolinska Institute and University Hospital in Stockholm, randomly assigned 2,017 women to either a standard chemotherapy group or a tailored dose-dense group. All of the participants had had surgery for node-positive or high-risk node-negative breast cancer.

After five years, 88.7 percent of the dose-dense group and 85.0 percent of the standard group were alive and had no recurrence of cancer. In addition, the researchers found that 86.7 percent of the dose-dense group had event-free survival at five years, compared with 82.1 percent of the standard group. Those in the dose-dense group reported worse quality of life on parameters like sexual functioning and side effects such as fatigue.

"Among women with high-risk early breast cancer, the use of tailored dose-dense chemotherapy compared with standard adjuvant chemotherapy did not result in a statistically significant improvement in breast cancer recurrence-free survival," the authors write. "Nonhematologic toxic effects were more frequent in the tailored dose-dense group."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »